Phase I Clinical Trial of the Immunocytokine EMD 273063 in Melanoma Patients

PURPOSE: To evaluate the safety, toxicity, in vivo immunologic activation, and maximum-tolerated dose (MTD) of EMD 273063 (hu14.18-IL-2) in patients with metastatic melanoma. PATIENTS AND METHODS: Thirty-three patients were treated with EMD 273063, a humanized anti-GD2 monoclonal antibody (mAb) link...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: King, David M., Albertini, Mark R., Schalch, Heidi, Hank, Jacquelyn A., Gan, Jacek, Surfus, Jean, Mahvi, David, Schiller, Joan H., Warner, Thomas, Kim, KyungMann, Eickhoff, Jens, Kendra, Kari, Reisfeld, Ralph, Gillies, Stephen D., Sondel, Paul
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2004
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2367368/
https://ncbi.nlm.nih.gov/pubmed/15483010
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2004.11.035
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak